NYSE:GMED - Globus Medical Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $52.61 +0.11 (+0.21 %) (As of 07/20/2018 04:59 AM ET)Previous Close$52.50Today's Range$52.11 - $52.6952-Week Range$27.79 - $57.55Volume354,400 shsAverage Volume673,656 shsMarket Capitalization$5.15 billionP/E Ratio40.07Dividend YieldN/ABeta0.53 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum. The company's disruptive technology products comprise products that allow for minimally invasive surgical techniques; and new treatment alternatives, including imaging, navigational, and robotic technologies, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous process spacer products. Its disruptive technology products also consist of regenerative biologics products, including bioactive glass-based bone void fillers and ceramic-collagen for pelvic/extremity and posterolateral spinal fusion procedures; and interventional pain management solutions, which comprise treatments for vertebral compression fractures. In addition, the company offers products for the treatment of orthopedic trauma, including compression screws, fixation plates, intramedullary nails, and external fixation systems. Further, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania. Receive GMED News and Ratings via Email Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical SymbolNYSE:GMED CUSIP37957720 Webwww.globusmedical.com Phone610-930-1800 Debt Debt-to-Equity RatioN/A Current Ratio7.45 Quick Ratio6.15 Price-To-Earnings Trailing P/E Ratio40.07 Forward P/E Ratio34.61 P/E Growth2.83 Sales & Book Value Annual Sales$635.98 million Price / Sales8.06 Cash Flow$1.7840 per share Price / Cash29.49 Book Value$10.01 per share Price / Book5.26 Profitability EPS (Most Recent Fiscal Year)$1.31 Net Income$107.34 million Net Margins18.05% Return on Equity14.51% Return on Assets13.13% Miscellaneous Employees1,500 Outstanding Shares97,470,000Market Cap$5,154.00 Globus Medical (NYSE:GMED) Frequently Asked Questions What is Globus Medical's stock symbol? Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED." How were Globus Medical's earnings last quarter? Globus Medical Inc (NYSE:GMED) issued its quarterly earnings results on Wednesday, May, 2nd. The medical device company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.36 by $0.05. The medical device company had revenue of $174.41 million for the quarter, compared to analyst estimates of $167.95 million. Globus Medical had a return on equity of 14.51% and a net margin of 18.05%. The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the company earned $0.32 EPS. View Globus Medical's Earnings History. What guidance has Globus Medical issued on next quarter's earnings? Globus Medical updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $1.52 from $1.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.50. The company issued revenue guidance of $695 million from $690 million, compared to the consensus revenue estimate of $690.92 million. What price target have analysts set for GMED? 12 analysts have issued twelve-month price objectives for Globus Medical's stock. Their predictions range from $36.00 to $65.00. On average, they anticipate Globus Medical's share price to reach $52.60 in the next year. This suggests that the stock has a possible downside of 0.0%. View Analyst Ratings for Globus Medical. What is the consensus analysts' recommendation for Globus Medical? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 2 sell ratings, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Globus Medical stock? Here are some recent quotes from research analysts about Globus Medical stock: 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (7/5/2018) 2. Canaccord Genuity analysts commented, "We recently had the opportunity to host a fireside chat with Globus, as well as visit the company’s booth during the AAOS conference and came away incrementally more confident in the growth opportunities ahead of the company. Specifically, early feedback and success with the ExcelsiusGPS system reinforce our view that the robotic platform can provide a tailwind to an improving core US spine business. In trauma, we were encouraged by the early excitement around the initial product launches – including 6 recently cleared systems to complement the 5 launched at OTA back in October – which we expect to develop into a growth driver in 2019 and beyond. Net, net, while the valuation certainly reflects continued execution in 2018, we are increasingly optimistic that the improving fundamentals in the core US spine business, early success in robotics, and OUS momentum are capable of delivering continued upside to current guidance – thus supporting continued share appreciation." (3/12/2018) 3. Needham & Company LLC analysts commented, "GMED’s 4Q17 revenue was consistent with its 1/9/18 preannouncement and its EPS beat consensus. Management reiterated 2018 revenue guidance of $690M and adjusted EPS guidance of $1.50. We estimate that the Emerging Technology segment drove much of the upside given the incremental revenue and negligible EPS drag. Gross margin was up 250 bps Y/Y and operating margin was up 60 bps Y/Y. We maintain our Hold rating since we believe that GMED’s valuation appropriately reflects its Emerging Technologies business’ potential." (2/22/2018) Who are some of Globus Medical's key competitors? Some companies that are related to Globus Medical include ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC) and Nevro (NVRO). Who are Globus Medical's key executives? Globus Medical's management team includes the folowing people: Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 51)Mr. David M. Demski, CEO & Director (Age 60)Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 47)Mr. David D. Davidar, Co-Founder & Director (Age 52)Mr. Daniel T. Scavilla, Sr. VP & CFO (Age 53) Has Globus Medical been receiving favorable news coverage? News headlines about GMED stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Globus Medical earned a news sentiment score of 0.06 on Accern's scale. They also gave media headlines about the medical device company an impact score of 45.79 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. Who are Globus Medical's major shareholders? Globus Medical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Retirement Systems of Alabama (0.10%), Gofen & Glossberg LLC IL (0.07%), Columbia Partners L L C Investment Management (0.07%), Nippon Life Global Investors Americas Inc. (0.04%), Municipal Employees Retirement System of Michigan (0.02%) and Essex Investment Management Co. LLC (0.02%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Institutional Ownership Trends for Globus Medical. Which institutional investors are selling Globus Medical stock? GMED stock was sold by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management, Municipal Employees Retirement System of Michigan, Conservest Capital Advisors Inc. and Gofen & Glossberg LLC IL. Company insiders that have sold Globus Medical company stock in the last year include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Insider Buying and Selling for Globus Medical. Which institutional investors are buying Globus Medical stock? GMED stock was acquired by a variety of institutional investors in the last quarter, including Nippon Life Global Investors Americas Inc., Essex Investment Management Co. LLC, Hartford Investment Management Co., Clarus Wealth Advisors, Bank of Montreal Can, Mckinley Capital Management LLC Delaware, Amalgamated Bank and Retirement Systems of Alabama. View Insider Buying and Selling for Globus Medical. How do I buy shares of Globus Medical? Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Globus Medical's stock price today? One share of GMED stock can currently be purchased for approximately $52.61. How big of a company is Globus Medical? Globus Medical has a market capitalization of $5.15 billion and generates $635.98 million in revenue each year. The medical device company earns $107.34 million in net income (profit) each year or $1.31 on an earnings per share basis. Globus Medical employs 1,500 workers across the globe. How can I contact Globus Medical? Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected] MarketBeat Community Rating for Globus Medical (NYSE GMED)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 360 (Vote Outperform)Underperform Votes: 298 (Vote Underperform)Total Votes: 658MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?